GH-axis stimulation
Clinical Research
Sermorelin has been used historically in GH-axis evaluation/treatment contexts. That history is not the same as current anti-aging approval.
Also known as Geref, GRF 1-29, sermorelin acetate
GHRH (1-29) analog that was previously marketed in the U.S. Current routine availability and approved status should not be assumed from historical branding.
Sermorelin is a 29–amino-acid fragment of GHRH. It was previously available as a U.S. product (Geref) used in diagnostic/therapeutic GH-axis contexts historically. Historical approval does not automatically mean a product is currently marketed or appropriate for unsupervised 'anti-aging' use. Confirm current regulatory and product status with official sources; this page does not treat compounding-clinic marketing as labeling.
Sermorelin is a shortened analog of natural GHRH that can stimulate pituitary GH release.
It is pharmacologically related to tesamorelin and CJC-1295 but is not the same molecule or the same modern labeled indication.
Historical FDA association with Geref is not a blanket endorsement of today's wellness-market vials.
Sermorelin is a shorter version of the hormone that tells the pituitary to release growth hormone. The pituitary still has to be able to respond.
Sermorelin binds GHRH receptors, stimulating endogenous GH pulses. Unlike exogenous GH, it depends on pituitary responsiveness. Historical diagnostic uses exploited that physiology. Wellness indications are not established by this educational page.
Step 1
Peptide
Sermorelin (GHRH 1-29 analog)
Step 2
Target
Pituitary GHRH receptor
Step 3
Pathway
Endogenous GH secretion
Step 4
Observed research effect
GH-axis stimulation in clinical/historical use contexts
Sermorelin has been used historically in GH-axis evaluation/treatment contexts. That history is not the same as current anti-aging approval.
Human GH-axis effects are pharmacologically expected and were used in historical clinical contexts. A contemporary, publicly summarized outcomes package comparable to tesamorelin's lipodystrophy program is not presented here.
GHRH-fragment pharmacology is well described as a class.
No sourced study cards have been attached yet. Information not sufficiently established at the study-card level.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice.
Long-term safety: Not sufficiently established.
Evidence limitations: Historical availability is often overstated in marketing. Check current official sources.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions.
Discovery
complete
GHRH 1-29 analog.
Human studies
complete
Historical clinical use as Geref-related product.
Regulatory status
in progress
Historical U.S. product association; current availability not assumed here.
It had a historical U.S. branded product. Current availability and labeled use should be verified with official sources. This page does not treat wellness compounding as equivalent to a current NDA product.
Growth Hormone Research
Growth hormone–releasing factor analog approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy — not a general weight-loss medicine.
View peptide →
Growth Hormone Research
Long-acting GHRH analog studied in healthy adults for prolonged GH and IGF-I secretion. Not an approved therapy for general use.
View peptide →